FDA announcements or Galderma's press releases

Galderma Gains FDA Approval for Nemluvio® to Treat Prurigo Nodularis

Aug 13, 2024, 05:09 AM

Galderma, a Swiss pharmaceutical company, has received approval from the U.S. Food and Drug Administration (FDA) for its drug Nemluvio® (nemolizumab). This medication is intended for adult patients suffering from Prurigo Nodularis, a chronic skin condition characterized by itchy nodules. The FDA approval marks a significant advancement for Galderma in the U.S. market, providing a new treatment option for patients with this challenging dermatological condition.